Name

Fermenta Biotech

Legal name

Fermenta Biotech Limited

Website

https://fermentabiotech.com

Company type

Public

Founded year

1951

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Vitamin D3 and Nutritional Ingredients Manufacturing

NAICS

Food Manufacturing (311)

SIC

Food And Kindred Products (2000)

akta.pro primary industry

Vitamins (A, B-Complex, C, D, E, K; Premixes) (AFAJAKAA)

akta.pro secondary industry

Vitamins & Minerals (Single Nutrients) (CRADAGAB)

Keywords

• Vitamin D3 manufacturing
• Pharmaceutical ingredients
• Nutritional premixes
• Biotech enzymes
• Animal feed additives

Headquarters

HQ city

Thane

HQ country

India

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Vitamin D3 and Related Ingredients: Manufacture and global supply of Vitamin D3 (cholecalciferol) in multiple variants — crystalline, oil, resin in oil, cold water dispersible (CWD), and feed grade powder — for pharmaceuticals, dietary/nutritional supplements, food fortification, feed, veterinary, and rodenticide applications. Also includes niche APIs such as Phenyramidol and Silicon Dioxide, Vitamin K1, Vitamin E50, and fish oil cholesterol.
2. Biotechnology / Enzyme Portfolio: Proprietary enzyme technologies (Fermase PS 250, Penicillin G Acylase, Dilbeads) delivered across the biopharmaceutical product lifecycle for manufacturing beta-lactam antibiotics, fine chemicals, bio-plastics, and cosmetics. Revenue from enzyme product sales and technology licensing.
3. Nutritional Premixes and Fortified Rice Kernel: Customised premixes for food fortification (staple food fortification, dietary supplements, RUTF, RUSF, bakery, confectionery, beverages, health food drinks) and Fortified Rice Kernel (FRK) manufacturing. Revenue from premix product sales and toll manufacturing.
4. Environmental Solutions: Comprehensive wastewater treatment solutions including design, engineering, procurement, construction, and operation & maintenance of STPs, WTPs, and ETPs. The environmental solutions business was sold to the wholly-owned subsidiary Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis effective October 1, 2025.
5. Real Estate: Property development and rental income from Thane One IT park (~200,000 sq ft leasable area, 100% occupied) and freehold land of ~5.5 acres. Tenants include Tata Technologies, Ashok Leyland, Samsung India, and Datamark BPO.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Fermenta Biotech Limited manufactures and sells Vitamin D3 (cholecalciferol), other vitamins (A, E), proprietary enzymes, and customized nutritional premixes for pharmaceutical, dietary supplement, food, and animal feed manufacturers globally. The company operates integrated manufacturing facilities in Kullu (Himachal Pradesh) and Dahej (Gujarat), India, and exports to 50-60 countries through subsidiaries in the USA and Germany.

Product overview

Fermenta Biotech is a manufacturer of pharmaceutical ingredients and nutritional products organized into five business segments: Vitamins and Other Ingredients (core business including Vitamin D3 variants, Vitamin K1, Vitamin E50, and niche APIs like Phenyramidol and Silicon Dioxide), Biotechnology (enzyme portfolio including Fermase enzymes and Novel Penicillin G Acylase for antibiotic synthesis), Nutrition (customized premixes, Fortified Rice Kernel, and Vitamin AD2 premix), Environmental Solutions (wastewater treatment plants and related services), and Real Estate (Thane One IT park). The company's flagship product is Vitamin D3 (Cholecalciferol) available in multiple variants including crystalline, oil, resin in oil, cold water dispersible, and feed grade powder. Recent product innovations include VITADEE GREEN (plant-based Vitamin D3 with patent protection) and VITADEE 100 SD (spray-dried variant with EDQM CEP). Fermenta also partnered with Solar Foods to introduce Solein protein bars in the US market.

Differentiator

Problem solved

Functional benefit

Brands

• VITADEE 100 SD: Spray-Dried variant of Vitamin D3 that received CEP from EDQM, enabling accelerated global growth.
• VITADEE Green
• Thane One
• Fermase PS 250
• Fermase PA 850
• Fermase PAR 450
• Dilbeads

Products and services

• Vitamin D3 (Cholecalciferol)

Quantifiable outcome

• Vitamin D3 Human Nutrition segment volumes grew 46% over 9MFY25, with 9MFY26 revenue reaching INR 413.6-421.2 crore and EBITDA up 86% YoY.
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Solar FoodscoreStrategic or Co-development Partner · 19 March 2026Fermenta partnered with Finnish startup Solar Foods to incorporate Solein CO2-derived protein into gluten-free protein bars for the US market. Solein is a protein ingredient made by feeding microbes on CO2, hydrogen and oxygen, yielding 78% protein content with minimal environmental footprint (1% of conventional meat emissions, 20% of plant proteins). The bars were planned for rollout in Q1 2026 in the US under Fermenta's health and performance nutrition brand.
• Fermenta Environment Solutions Private Limited (FESPL)coreStrategic or Co-development Partner · 19 September 2025Fermenta sold its environmental solutions business operations to its wholly-owned subsidiary Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis effective October 1, 2025. FESPL was incorporated on May 1, 2025. This transfer enables focused management of the environmental solutions business.
• Aurigene Pharmaceutical Services Limited (Dr. Reddy's Laboratories)coreStrategic or Co-development Partner · 31 December 2022Fermenta exclusively licensed its enzymatic technology for manufacturing Molnupiravir to Aurigene Pharmaceutical Services Limited, a step-down subsidiary of Dr. Reddy's Laboratories Limited. This follows Fermenta's development and patent filing of the enzymatic synthesis process for the COVID-19 drug.
• Global Alliance for Improved Nutrition (GAIN)coreGTM or Marketing PartnerFermenta received the Letter of Approval (LOA) from GAIN as a supplier of dry and liquid premix blends. This prestigious certification recognises Fermenta's commitment to global benchmarks of quality, food safety, and nutritional excellence, enabling access to international food fortification programs and public health nutrition initiatives.
• National Institute of Food Technology, Entrepreneurship and Management – Thanjavur (NIFTEM-T)minorStrategic or Co-development PartnerFermenta entered into a strategic Memorandum of Understanding (MoU) with NIFTEM-T to strengthen India's food fortification landscape. The partnership leverages NIFTEM-T's academic and research expertise in food technology alongside Fermenta's manufacturing capabilities in nutritional premixes and fortified rice kernel.
• MUFG Intime India Private LimitedminorOthersMUFG Intime India Private Limited serves as the Registrar and Transfer Agent (RTA) for Fermenta Biotech Limited, handling investor service requests, share transfers, IEPF filings, and KYC updates.

Scale indicators13 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Zhejiang NHU Company: One of the world's largest manufacturers of Vitamin D3 and other vitamins/intermediates based in China. Directly competes with Fermenta in feed-grade and crystalline Vitamin D3 supply across global pharmaceutical, food, and feed channels.
• Dishman Carbogen Amcis: Indian API and contract manufacturer with vitamins, niche APIs, and biocatalysis capabilities serving global pharmaceutical and nutraceutical customers. Closest India-based peer in terms of API/vitamin manufacturing and export orientation.
• dsm-firmenich: Global leader in nutritional ingredients including Vitamin D3 (cholecalciferol) and a broad premix/fortification portfolio. Most direct competitor to Fermenta's core vitamin and nutrition business, with overlapping pharma, food, and feed applications.
• Taizhou Hisound Chemical: Chinese specialty chemical producer focused on Vitamin D3 and cholecalciferol derivatives for nutraceutical and pharmaceutical applications. Direct peer in the global Vitamin D3 bulk API market where pricing and capacity decisions shape Fermenta's economics.

Broad incumbents

• Novonesis (formerly Novozymes): Global leader in industrial enzymes and microbial solutions serving pharmaceuticals, food, and bio-based manufacturing. Comparable to Fermenta's Fermase enzyme portfolio and Dilbeads immobilisation technology targeting beta-lactam antibiotic synthesis.
• Glanbia Nutritionals: Global nutritional solutions provider offering premixes, customised nutrient blends, and functional ingredients for food, beverage, and supplement brands. Comparable to Fermenta's nutrition/premix and food fortification business, though at much larger scale and broader geographic footprint.
• Kerry Group: Global taste and nutrition company supplying premixes, functional ingredients, and fortification solutions to food and beverage customers. Overlaps with Fermenta's customised premix business serving bakery, beverages, and health food drinks.
• BASF: Major global chemicals and nutrition company producing vitamins (including D3), enzymes, and a wide portfolio of nutritional and food ingredients. Overlaps with Fermenta in vitamins, enzymes, and premixes but operates across many more verticals.

Regional players

• Aurobindo Pharma: Large Indian pharmaceutical company with API, generic formulations, and nutraceutical exposure. Comparable as an Indian-listed pharma/ingredients peer operating across regulated global markets, although Aurobindo is far larger and more diversified.

Emerging players

• Solar Foods: Finnish startup producing Solein CO2-derived protein; Fermenta has a strategic partnership to incorporate Solein into US-market gluten-free protein bars. Comparable as an emerging nutrition/ingredient partner rather than a direct competitor, sharing the plant-based, sustainability-led value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/fermentabiotech
• Facebookfacebook.com/259024240903981
• LinkedInlinkedin.com/company/fermenta-biotech-ltd

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fermenta Biotech